Vol. 2 No. 4 (2025)

Research Articles

CYP2C19 Gene Polymorphism in Patients with Digestive Disease from Hezhou Area

Published 2025-08-31

  • Min Deng
    • ,
  • Wenjian Zhou
    • ,
  • Qiuyan Wei
    • ,
  • Peng Li
    • ,
  • Nianyi Ye

Min Deng
Department of Digestive Diseases, The People’s Hospital of Hezhou, Hezhou 542800, China

Wenjian Zhou
Department of Pharmacy, The People’s Hospital of Hezhou, Hezhou 542800, China

Qiuyan Wei
Department of Pharmacy, The People’s Hospital of Hezhou, Hezhou 542800, China

Peng Li
School of Design, Hezhou University, Hezhou 542800, China

Nianyi Ye
Department of Digestive Diseases, The People’s Hospital of Hezhou, Hezhou 542800, China

Abstract

The CYP2C19 gene, characterized by high polymorphism, plays a key role in interindividual variability in drug response, particularly for proton pump inhibitors (PPIs). However, data on CYP2C19 genetic distribution in the local Hezhou population of Guangxi Province remain limited. This study aimed to identify CYP2C19 polymorphisms in digestive disease patients in Hezhou and compare genotype prevalence across populations to clarify allele distribution patterns and optimize prescription strategies. A total of 95 patients with digestive disorders were analyzed using high-throughput sequencing to detect CYP2C19 variants, and genotype distribution was further compared across different ethnic groups. The allele frequencies of CYP2C19*1, *2, *3, and *17 were 93.68%, 40%, 8.42%, and 7.37%, respectively. In terms of metabolic phenotypes, normal metabolizers (*1/*1) comprised 47.37%, rapid metabolizers (*1/*17) 6.32%, intermediate metabolizers (*1/*2, *1/*3, *2/*17) 41.05%, and poor metabolizers (*2/*2, *2/*3) 5.26%. Statistical analysis revealed no significant differences in genotype distribution between males and females (p=0.548), across six digestive disease categories (p=0.956), or between Helicobacter pylori-positive and -negative groups (p=0.160). These findings suggest that CYP2C19 polymorphism is prevalent in the Hezhou population but shows no significant association with sex, digestive disease subtype, or H. pylori infection status. The results provide insight into the genetic landscape of CYP2C19 in this region and highlight the importance of considering genetic background in guiding rational PPI use, while also serving as a reference for personalized treatment strategies in populations with similar genetic structures.

Keywords

vitamin D receptor, polymorphism, breast cancer, meta-analysis

PDF

References

  1. Velmovitsky PE, Bevilacqua T, Alencar P, Cowan D, Morita PP. Convergence of Precision Medicine and Public Health Into Precision Public Health: Toward a Big Data Perspective. Front Public Health. 2021;9:561873.
  2. Döhner H, Wei AH, Löwenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18(9):577–90.
  3. Weldy CS, Ashley EA. Towards precision medicine in heart failure. Nat Rev Cardiol. 2021;18(11):745–62.
  4. Ahmad T, Valentovic MA, Rankin GO. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol. 2018;153:196–204.
  5. Stajnko A, Runkel AA, Kosjek T, Snoj Tratnik J, Mazej D, Falnoga I, et al. Assessment of susceptibility to phthalate and DINCH exposure through CYP and UGT single nucleotide polymorphisms. Environ Int. 2022;159: 107046.
  6. Gao B, Tan T, Cao X, Pan M, Yang C, Wang J, et al. Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions. BMC Med Genom. 2022;15(1):23.
  7. Sapone A, Vaira D, Trespidi S, Perna F, Gatta L, Tampieri A, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol. 2003;98(5):1010–5.
  8. Ozdil B, Akkiz H, Bayram S, Bekar A, Akgöllü E, Sandikçi M. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication. Turk J Gastroenterol. 2010;21(1):23–8.
  9. Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, Droździk M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol. 2006;62(10):877–80.
  10. Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57.
  11. Yuan XW, Yuan SY, Wu GX, Wu ZX, Guan ZY. Genetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong Province. Hematology. 2022;27(1):1056–61.
  12. Zhang YD, Dong QW, Zhang SH, Gu F, Zhang Y, Song HB, et al. Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory Helicobacter pylori infection. Zhonghua Er Ke Za Zhi. 2020;58(1):41–5 (Chinese).
  13. Ima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, et al. Clinical pharmacogenetics implementation consortium (CPIC) Guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther. 2021;109(6):1417–23.
  14. Wang P, Feng SB, Jin Y. CYP2C19 gene polymorphism and susceptibility to gastric cancer after helicobacter pylori infection. Chinese J Nosocomiol. 2020;30(2):170–3.
  15. Tong TG, Zhang RL, Fu GF. The distribution characteristics of CYP2C19 gene polymorphism in Hp positive gastric cancer patients. Modern Diag Treat. 2017;28(11):2116–7.
  16. Wang Xianghui, Yu Jing, Gao Ruofei.Effect of CYP2C19 gene polymorphism on the efficacy of omeprazole in the treatment of pediatric gastric ulcer [J]. Experimental and Clinical Medicine, 2020,38(2):286-288.
  17. Cao Shaohua, Gao Xuede, Zhang Jinran, et al.Relationship between CYP2C19 gene polymorphism and the efficacy of proton pump inhibitor therapy in gastroesophageal reflux disease [J]. Modern Digestive and Interventional Therapy, 2020,25(7):889-892.
  18. Peng Jinwei, Zhou Baozhu, Liao Guobin et al.Effect of CYP2C19 gene polymorphism on the efficacy of esomeprazole in treating gastroesophageal reflux disease [J]. Chinese Journal of Modern Applied Pharmacy, 2020,37(18):2254-2257.
  19. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics Working group. Clin Transl Sci. 2020;13(1):116–24.
  20. PharmGKB. CYP2C19 clinical annotations. 2021. https://www.pharmgkb.org/gene/PA124/clinicalAnnotation.
  21. PharmGKB. Drug Label Information and Legend. 2020. https://www.pharmgkb.org/
  22. Zhen Yang,Yunqian Xie, Daya Zhang, et al.CYP2C19 gene polymorphism in Ningxia.Pharmacological Reports (2023) 75:705–714.
  23. Zhong Z, Hou J, Li B, Zhang Q, Liu S, Li C, et al. Analysis of CYP2C19 genetic polymorphism in a large ethnic hakka population in Southern China. Med Sci Monit. 2017;23:6186–92.
  24. He N, Yan FX, Huang SL, Wang W, Xiao ZS, Liu ZQ, et al. CYP2C19 genotype and S-mephenytoin 4’-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol. 2002;58(1):15–8.
  25. Jin T, Zhang X, Geng T, Shi X, Wang L, Yuan D, et al. Genotypep-henotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy. Mol Med Rep. 2016;13(3):2117–23.
  26. Ding Y, Xu D, Zhang X, Yang H, Geng T, He P, et al. Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population. Int J Clin Exp Pathol.2015;8(10):13201–8.
  27. Zuo LJ, Guo T, Xia DY, Jia LH. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers. 2012;16(2):102–8.
  28. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics. 1996;6(6):547–51.
  29. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60(6):661–6.
  30. Yamada S, Onda M, Kato S, Matsuda N, Matsuhisa T, Yamada N, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol. 2001;36(10):669–72.
  31. Sukasem C, Tunthong R, Chamnanphon M, Santon S, Jantararoungtong T, Koomdee N, et al. CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmgenom Pers Med. 2013;6:85–91.
  32. Pang YS, Wong LP, Lee TC, Mustafa AM, Mohamed Z, Lang CC. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br J Clin Pharmacol. 2004;58:332–5.
  33. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Cau-casians: comparison with S-mephenytoin hy-droxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 1995;5:358–63.
  34. Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004;50:195–200.
  35. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003;59:303–12.
  36. Bravo-Villalta HV, Yamamoto K, Nakamura K, Bayá A, Okada Y, Horiuchi R. Genetic polymor-phism of CYP2C9 and CYP2C19 in a Bolivian population: An investigative and comparative study. Eur J Clin Pharmacol. 2005;61:179–84.
  37. Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol. 2005;61:491–7.
  38. Favela-Mendoza AF, Martinez-Cortes G, Hernandez-Zaragoza M, Salazar-Flores J, Muñoz-Valle JF, Martinez-Sevilla VM, et al. Genetic variability of CYP2C19 in a Mexican population: Contribution to the knowl-edge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype. J Genet. 2015;94:1–5.
  39. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, et al. Low frequency of defec-tive alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999;66:185–92.
  40. Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther. 1998;64:391–401.
  41. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hy-droxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics. 1996;6:521–6.
  42. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Pheno-typing and genotyping of S-mephenytoin hy-droxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther. 1995;57:656–61.
  43. Sanford JC, Guo Y, Sadee W, Wang D. Regulatory polymorphisms in CYP2C19 afecting hepatic expression. Drug Metabol Drug Interact. 2013;28(1):23–30.
  44. Negovan Anca, Iancu Mihaela, Moldovan Valeriu, et al. Infuence of MDR1C3435T, CYP2C19*2 and CYP2C19*3 gene polymorphisms and clinical characteristics on the severity of gastric lesions: a case control study. J Gastrointest Liver Dis JGLD.2016; 25(2):258–60.
  45. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, et al. Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;22(10):1033–40.
  46. Jiang X R, Zhang Y G, Lu J, et al. Analysis of CYP2C19 gene polymorphisms in gastrointestinal diseases among Han Chinese in northern China[J]. J Clin Experim Pathol. 2016;32(10):1101–1104,1109.
  47. Lirong Mo. Investigation of the current status of Helicobacter pylori infection in the population of Wuzhong City. Ningxia and analysis of related factor: Ningxia Medical University; 2019.

Similar Articles

You may also start an advanced similarity search for this article.